A 32-year-old male, known case of chronic myeloid leukemia (CML) on Imatinib with irregular compliance for 6 years, presented with painless swellings over the scalp, face and trunk for 3-weeks. He had non-tender, purplish nodules and plaques of varying sizes over the scalp, face and trunk giving ''blueberry muffin'' appearance (Fig. 1a) . Hemoglobin was 8.3 g/dL; TLC 66,900/mm3 and platelets 70,000/mm3. Biopsy from skin nodule was suggestive of leukemia cutis (Fig. 2a, b) . Bone marrow showed CML in chronic phase (Fig. 2c, d ). Because of poor finances, he was counseled regarding compliance and imatinib dose was increased to 800 mg/day. Six weeks later, the complete hematological response was achieved, and skin lesions gradually resolved to hyperpigmented macules (Figure 1b) .
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